Mathieu F Chevalier

12PUBLICATIONS
72CO-AUTHORS
Innate immunityHost-parasite interactionsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Nov 24, 2025
Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines.

Agathe Carrier, Paolo Manghi, Carolina Alves Costa Silva

|Mar 05, 2025
Donor HLA-DQ genetic and functional divergence affect the control of BK polyoma virus infection after kidney transplantation.

Mathieu F Chevalier, Vincent Allain, Julien Gras

|Dec 15, 2023
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.

Laurent Derré, Ilaria Lucca, Valérie Cesson

|Aug 24, 2022
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.

Sylvain Nguyen, Mathieu F Chevalier, Sulayman Benmerzoug

|Jul 12, 2022
Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse.

Viviane Gournay, Nicolas Vallet, Vivien Peux

|Jun 21, 2022
Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.

Alexis Cuffel, Vincent Allain, Lionel Faivre

Pageof 2

Frequent Collaborators

6 joint publications

Sophie Caillat-Zucman

5 joint publications

Laurent Derré

3 joint publications

Juliette Villemonteix

2 joint publications

Agathe Carrier